The right flank tumor was then injected with 30μg of the TLR9 agonist MGN1703 or PBS on days 3, 6 and 9 with or without concordant injection of 100μg of the CTLA-4 antibody 9D9-mIgG2a systemically. This evidence concerns the gene TLR9 and neoplasm.